Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features Correspondence

  

Authors:	Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
Title:	Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
Keywords:	adult; clinical article; human tissue; middle aged; unclassified drug; prednisone; clinical feature; fatigue; neutropenia; case report; salvage therapy; doxorubicin; cytarabine; rituximab; cancer staging; neurotoxicity; positron emission tomography; letter; protein bcl 2; multiple cycle treatment; bendamustine; cyclophosphamide; dexamethasone; hemoglobin; vincristine; pathology; cell population; protein p53; hodgkin disease; b lymphocyte; axillary lymph node; intensive care unit; germinal center; cd20 antigen; bone lesion; acute graft versus host disease; nonhodgkin lymphoma; fluorescence in situ hybridization; bone marrow biopsy; lymphoma, non-hodgkin; chromatin; laboratory test; myc protein; lymph node; splenomegaly; graft versus host reaction; allogeneic hematopoietic stem cell transplantation; protein bcl 6; lymphoma, large b-cell, diffuse; oxaliplatin; diaphragm; granulocyte colony stimulating factor; follicular lymphoma; thorax wall; disease exacerbation; lymphadenopathy; cd19 antigen; night sweat; interferon regulatory factor 4; programmed death 1 ligand 1; international prognostic index; lymphoid cell; bloating; antibody conjugate; immunoconjugates; eosinophil; cytokine release syndrome; diffuse large b cell lymphoma; body weight loss; tocilizumab; brentuximab vedotin; transcription factor pax5; nivolumab; humans; human; male; organic cation transporter 2; polatuzumab vedotin; loss of appetite; tumor necrosis factor receptor superfamily member 8; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel; anakinra; lmp1 protein
Journal Title:	Leukemia and Lymphoma
Volume:	63
Issue:	13
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2022-01-01
Start Page:	3241
End Page:	3244
Language:	English
DOI:	10.1080/10428194.2022.2113528
PUBMED:	36120859
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85138326330&doi=10.1080%2f10428194.2022.2113528&partnerID=40&md5=467b49e9a334b3d7d31fd0e32e20bba5
Notes:	Letter -- Export Date: 3 January 2023 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201937